Trials / Completed
CompletedNCT03215173
Fit After Baby: Increasing Postpartum Weight Loss in Women at Increased Risk for Cardiometabolic Disease
Fit After Baby: A Randomized Controlled Trial of a Mobile Health Intervention to Increase Postpartum Weight Loss in Women at Increased Risk for Cardiometabolic Disease
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 82 (actual)
- Sponsor
- University of Colorado, Denver · Academic / Other
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This study plans to learn more about how to increase postpartum weight loss and how to decrease risk factors for postpartum women at increased risk for diabetes and heart disease. The program is delivered using a mobile application (app) and a lifestyle coach. This mobile application is developed for women who are at higher risk for diabetes and heart disease. Women who have gestational diabetes, (diabetes during pregnancy, or GDM), gestational hypertension (high blood pressure), and/or preeclampsia (high blood pressure and protein in the urine), and/or small-for gestational-age, and/or preterm (early) delivery during their pregnancies have a higher risk for diabetes and heart disease. This mobile application was developed using the latest research studies and using the evidence-based Diabetes Prevention and Colorado Weigh programs. The goal of the program is to help women lose weight and participate in physical activity after delivery.
Conditions
- Cardiovascular Diseases
- Diabetes
- Gestational Diabetes
- Preeclampsia
- Gestational Hypertension
- Small for Gestational Age at Delivery
- Preterm Birth
- Overweight and Obesity
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Fit After Baby | Mobile application |
| BEHAVIORAL | Text4Baby Control Group | Receive free text messages |
Timeline
- Start date
- 2017-09-01
- Primary completion
- 2020-11-30
- Completion
- 2020-11-30
- First posted
- 2017-07-12
- Last updated
- 2021-03-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03215173. Inclusion in this directory is not an endorsement.